These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21446041)

  • 21. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I; Marciniak RA
    Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7.
    Cui DD; Huang Y; Mao SH; Chen SC; Qiu M; Ji LL; Yi C
    Braz J Med Biol Res; 2009 Sep; 42(9):854-62. PubMed ID: 19738990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells.
    Lin CI; Whang EE; Abramson MA; Donner DB; Bertagnolli MM; Moore FD; Ruan DT
    Biochem Biophys Res Commun; 2009 Feb; 379(2):626-31. PubMed ID: 19124005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells.
    Fandy TE; Shankar S; Srivastava RK
    Mol Cancer; 2008 Jun; 7():60. PubMed ID: 18590557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
    Voelkel-Johnson C
    Cancer Biol Ther; 2003; 2(3):283-90. PubMed ID: 12878867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines.
    Keane MM; Rubinstein Y; Cuello M; Ettenberg SA; Banerjee P; Nau MM; Lipkowitz S
    Breast Cancer Res Treat; 2000 Nov; 64(2):211-9. PubMed ID: 11194457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
    Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
    Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells.
    Komdeur R; Meijer C; Van Zweeden M; De Jong S; Wesseling J; Hoekstra HJ; van der Graaf WT
    Int J Oncol; 2004 Sep; 25(3):677-84. PubMed ID: 15289869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480.
    Xu LH; Deng CS; Zhu YQ; Liu SQ; Liu DZ
    World J Gastroenterol; 2003 Jun; 9(6):1241-5. PubMed ID: 12800232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
    Ruiz de Almodóvar C; Ruiz-Ruiz C; Rodríguez A; Ortiz-Ferrón G; Redondo JM; López-Rivas A
    J Biol Chem; 2004 Feb; 279(6):4093-101. PubMed ID: 14623878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
    Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
    Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
    Malin D; Chen F; Schiller C; Koblinski J; Cryns VL
    Clin Cancer Res; 2011 Aug; 17(15):5005-15. PubMed ID: 21653692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer.
    Wu XX; Kakehi Y; Mizutani Y; Kamoto T; Kinoshita H; Isogawa Y; Terachi T; Ogawa O
    Int J Oncol; 2002 May; 20(5):949-54. PubMed ID: 11956588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand.
    Li LC; Jayarama S; Pilli T; Qian L; Pacini F; Prabhakar BS
    Thyroid; 2013 Jan; 23(1):70-8. PubMed ID: 22998497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J; Bu J; Hao Y; Chen F
    Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
    Kim K; Fisher MJ; Xu SQ; el-Deiry WS
    Clin Cancer Res; 2000 Feb; 6(2):335-46. PubMed ID: 10690508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.
    Piggott L; Omidvar N; Martí Pérez S; French R; Eberl M; Clarkson RW
    Breast Cancer Res; 2011 Sep; 13(5):R88. PubMed ID: 21914219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers.
    Lin T; Zhang L; Davis J; Gu J; Nishizaki M; Ji L; Roth JA; Xiong M; Fang B
    Mol Ther; 2003 Sep; 8(3):441-8. PubMed ID: 12946317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer.
    Zhu J; Zhou Q; Tan S
    Cancer Lett; 2016 Dec; 383(2):154-160. PubMed ID: 27693456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.
    French R; Hayward O; Jones S; Yang W; Clarkson R
    Mol Cancer; 2015 Dec; 14():209. PubMed ID: 26667821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.